Cargando...

Beneficial effects of elafibranor on NASH in E3L.CETP mice and differences between mice and men

Non-alcoholic steatohepatitis (NASH) is the most rapidly growing liver disease that is nevertheless without approved pharmacological treatment. Despite great effort in developing novel NASH therapeutics, many have failed in clinical trials. This has raised questions on the adequacy of preclinical mo...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Sci Rep
Main Authors: van den Hoek, Anita M., Verschuren, Lars, Caspers, Martien P. M., Worms, Nicole, Menke, Aswin L., Princen, Hans M. G.
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group UK 2021
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7930243/
https://ncbi.nlm.nih.gov/pubmed/33658534
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-021-83974-8
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!